Skip to content

Study · Not a test of the peptide alone · 2018

7 results

Anti-HBV effect of interferon-thymosin α1 recombinant proteins in transgenic Dunaliella salina in vitro and in vivo.

Zhang Z, He P, Zhou Y, Xie X, Feng S, Sun C

Experimental and therapeutic medicine29 May 2018Cited by 3 (Europe PMC)

PMID30112022 (opens in a new tab)PMCIDPMC6090406 (opens in a new tab)DOI10.3892/etm.2018.6227 (opens in a new tab)PepBankPUB-30112022
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In ducks infected with duck HBV, serum DHBV-DNA was lower with the transgenic algae preparation (20 g/kg) than with control at 7, 14 and 21 days.

    In plain wordsIn infected ducks, a preparation with an interferon-thymosin alpha1 fusion lowered viral DNA in blood more than control.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum DHBV-DNA
    Study

    duckn: not reported in source

    DHBV-infected ducks
    Comparator
    Control
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    In addition, the DHBV-infected duck model experiments indicated that serum DHBV-DNA levels were significantly decreased in the group of TDS (20 g/kg) following treatment for 7, 14 and 21 days compared with the control group.
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In ducks infected with duck HBV, serum DHBV-DNA did not relapse 5 days after withdrawal of the preparation in the medium and high dose groups.

    In plain wordsIn infected ducks, viral DNA did not return 5 days after stopping a preparation with an interferon-thymosin alpha1 fusion.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDHBV-DNA relapse after drug withdrawal
    Study

    duckn: not reported in source

    DHBV-infected ducks
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    Following withdrawal of the drug for 5 days, the levels of DHBV-DNA did not relapse in the medium and high dose groups of TDS (10 and 20 g/kg, respectively).
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In ducks infected with duck HBV, the transgenic algae preparation and IFN-α alleviated liver inflammation on histology.

    In plain wordsIn infected ducks, a preparation with an interferon-thymosin alpha1 fusion eased liver inflammation.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLiver inflammation
    Study

    duckn: not reported in source

    DHBV-infected ducks
    Outcome group
    Inflammation markers · Liver

    Source sentences

    Summary
    Histological analysis of duck liver also demonstrated that TDS and IFN-α treatment alleviated inflammation
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In ducks infected with duck HBV, the transgenic algae preparation and IFN-α reduced HBsAg signals in the liver.

    In plain wordsIn infected ducks, a preparation with an interferon-thymosin alpha1 fusion reduced hepatitis B surface protein signals in the liver.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBsAg signals in liver
    Study

    duckn: not reported in source

    DHBV-infected ducks
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    Histological analysis of duck liver also demonstrated that TDS and IFN-α treatment alleviated inflammation and HBsAg signals in duck livers.
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In HepG2.2.15 cells, the transgenic algae preparation with interferon-thymosin α1 reduced cell viability.

    In plain wordsIn cells, a preparation with an interferon-thymosin alpha1 fusion lowered cell viability.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHepG2.2.15 cell viability
    Study

    n: not reported in source

    HepG2.2.15 cells
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    The results demonstrated that TDS suppressed cell viability and HBsAg and HBeAg secretion in HepG2.2.15 cells.
    1 context sentence
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In HepG2.2.15 cells, the transgenic algae preparation with interferon-thymosin α1 suppressed HBsAg secretion, with a treatment index greater than that of IFN-α.

    In plain wordsIn cells, a preparation with an interferon-thymosin alpha1 fusion lowered a hepatitis B surface protein, with a larger index than interferon-alpha.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBsAg secretion
    Study

    n: not reported in source

    HepG2.2.15 cells
    Comparator
    IFN-α
    Outcome group
    Antiviral activity · Infection

    Measurements

    Treatment index for HBsAg
    2.96
    TDS

    Source sentences

    Summary
    The results demonstrated that TDS suppressed cell viability and HBsAg and HBeAg secretion in HepG2.2.15 cells.
    2 context sentences
    Summary · context
    Furthermore, the treatment index values for HBsAg and HBeAg following TDS treatment were 2.96 and 3.07 respectively, which were greater than those of the IFN-α treated group.
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In HepG2.2.15 cells, the transgenic algae preparation with interferon-thymosin α1 suppressed HBeAg secretion, with a treatment index greater than that of IFN-α.

    In plain wordsIn cells, a preparation with an interferon-thymosin alpha1 fusion lowered a hepatitis B early protein, with a larger index than interferon-alpha.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHBeAg secretion
    Study

    n: not reported in source

    HepG2.2.15 cells
    Comparator
    IFN-α
    Outcome group
    Antiviral activity · Infection

    Measurements

    Treatment index for HBeAg
    3.07
    TDS

    Source sentences

    Summary
    The results demonstrated that TDS suppressed cell viability and HBsAg and HBeAg secretion in HepG2.2.15 cells.
    2 context sentences
    Summary · context
    Furthermore, the treatment index values for HBsAg and HBeAg following TDS treatment were 2.96 and 3.07 respectively, which were greater than those of the IFN-α treated group.
    Summary · context
    The aim of the present study was to investigate the anti-hepatitis B virus (HBV) effect of interferon (IFN)-thymosin α1 (TA1) in a transgenic Dunaliella salina (TDS) system in vitro and in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.